Lilly Announces Details of Presentations at 2021 American Association for Cancer Research (AACR)

Presentation of Phase 1/2 LIBRETTO-001 trial data will highlight safety and efficacy data of Retevmo® (selpercatinib) in the treatment of RET fusion-positive cancers outside of lung and thyroid cancer Preclinical characterization data will be presented for oral SERD, BCL2 inhibitor, next-generation